Labcorp Holdings Inc. (NYSE:LH) Announces $0.72 Quarterly Dividend

Labcorp Holdings Inc. (NYSE:LH) announced a quarterly dividend on Thursday, July 9th. Investors of record on Friday, August 28th will be paid a dividend of 0.72 per share by the medical research company on Friday, September 11th. This represents a c) dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Friday, August 28th.

Labcorp has a payout ratio of 16.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Labcorp to earn $19.33 per share next year, which means the company should continue to be able to cover its $2.88 annual dividend with an expected future payout ratio of 14.9%.

Labcorp Trading Down 0.1%

NYSE:LH opened at $277.51 on Friday. The stock’s 50 day moving average price is $263.69 and its 200 day moving average price is $267.01. The company has a market capitalization of $22.76 billion, a PE ratio of 24.58, a P/E/G ratio of 1.94 and a beta of 0.89. The company has a quick ratio of 1.54, a current ratio of 1.73 and a debt-to-equity ratio of 0.68. Labcorp has a 52-week low of $241.81 and a 52-week high of $293.72.

Labcorp (NYSE:LH) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. The company had revenue of $3.54 billion during the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.84 earnings per share. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. On average, research analysts anticipate that Labcorp will post 18 EPS for the current year.

Insider Activity

In other news, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the sale, the chief executive officer owned 107,234 shares of the company’s stock, valued at $27,291,053. The trade was a 5.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 92 shares of the business’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $26,329.48. Following the transaction, the executive vice president owned 3,904 shares in the company, valued at approximately $1,117,285.76. This trade represents a 2.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 6,991 shares of company stock valued at $1,796,696 over the last quarter. Corporate insiders own 0.84% of the company’s stock.

Hedge Funds Weigh In On Labcorp

A number of large investors have recently modified their holdings of the business. Victory Capital Management Inc. grew its holdings in Labcorp by 103.1% during the fourth quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock worth $1,343,922,000 after acquiring an additional 2,719,475 shares during the period. Boston Partners acquired a new stake in Labcorp in the fourth quarter valued at $480,271,000. Norges Bank purchased a new stake in shares of Labcorp during the 4th quarter worth $248,006,000. Wellington Management Group LLP boosted its position in shares of Labcorp by 15.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after purchasing an additional 289,029 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Labcorp by 79.1% during the 3rd quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company’s stock worth $178,996,000 after purchasing an additional 275,454 shares during the period. 95.94% of the stock is owned by hedge funds and other institutional investors.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.